WebJun 1, 2024 · Methods: AGILE is a global, randomized, double-blind, placebo-controlled trial in patients with previously untreated mIDH1 AML who are candidates for nonintensive … WebJun 16, 2024 · The AGILE trial showed a clear advantage with a median overall survival of over 24 months and markedly enhanced outcomes on every parameter looked at, favoring the ivosidenib and azacitidine.
AGILE:
WebDec 20, 2024 · Results presented from the AGILE trial at the 2024 ASH conference revealed that the combination of ivosidenib and azacitidine in those with newly diagnosed IDH-1 mutated AML who cannot undergo intensive induction chemotherapy produced an average overall survival that was approximately three times longer than patients who … WebThe AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? Transl Oncol. 2024 Sep 2;25:101523. doi: … blu ray media players
Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combin…
WebNov 23, 2024 · Volume 138, Issue Supplement 1. November 23 2024. ISSN 0006-4971. EISSN 1528-0020. In this Issue. Plenary Abstracts. Oral Abstracts. WebDec 13, 2024 · AGILE LACEWING PANTHER. Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, talks on major trial outcomes in the acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS) space that were shared at the ASH 2024 annual meeting. Dr Cluzeau comments on the negative Phase III PANTHER trial … WebJun 4, 2024 · Significant clinical benefit has been shown with ivosidenib (Tibsovo), a potent oral targeted inhibitor of IDH1, plus azacitidine (AZA; Vidaza) vs placebo plus azacitidine in patients with newly-diagnosed IDH1-mutant acute myeloid leukemia (AML), according to findingd from the phase 3 AGILE trial (NCT03173248). 1. Results from AGILE supported … cle southwest